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     Abstract   
Background: Human lipoprotein receptor-related protein -6 (LRP6) plays a role in the development of coronary 
artery disease. This study aimed to determine the serum level of the LRP6 in patients referred to the coronary 
angiogram taking into considerations the findings of coronary angiography, evidence of dyslipidemia, obesity and 
co-existed diabetes mellitus. 
Methods: This cross-sectional study included 96 patients who referred to coronary angiogram as an interventional 
diagnostic test for coronary artery disease. The patients were grouped into Group I (negative angiogram); Group 
IIA (non-obstructed coronary vessels, positive angiogram) and: Group IIB (obstructed coronary vessels, positive 
angiogram).  The anthropometric measurement, blood pressure, and fasting serum lipid profile and glucose were 
determined. The serum levels of LRP6 were determined by using the Enzyme-Linked ImmunoSorbent Assay 
(ELISA).   
Results: A non-significant higher serum level of LRP6 observed in patients with a positive angiogram 0.175 ± 
0.074 ng/ml (Group IIA) and 0.166 ± 0.063 ng/ml (Group IIB) compared with the negative angiogram (Group I: 
0.160 ± 0.019 ng/ml). The area under the curve of LRP6 in patients with positive angiogram was significantly lower 
than that with a normal angiogram. 
Conclusion: We conclude that the serum level of LRP6 is a good discriminator of patients with coronary artery 
disease as the area under the curve of the serum levels of LRP6 is significantly decreased as the number of 
occluded coronary vessels increased.  
Keywords: Coronary artery angiogram, coronary artery occlusion, low density lipoprotein receptor related gene-6, 
myocardial ischemia. 
 
Background   
The Wingless/integrated (Wnt) signaling pathways are made of 
proteins which included the canonical and non-canonical 
pathways. These pathways are activated by binding a Wnt 
protein ligand to a receptor related to the Frizzled family. These 
pathways play a role in the regulation of the cell development, 
shape and migration [1,2]. Co-receptors, including lipoprotein 
receptor related protein (LRP) 5/6 are required to facilitate the 
interaction between the Wnt binding protein and the Frizzled 
receptor [3]. Activation of a canonical pathway (Wnt/β-catenin 
signaling) leads to accumulation and phosphorylation of 
cytosolic β-catenin and then translocated into the nucleus [4,5]. 
Therefore, LRP6 plays a role in the stability of β-catenin protein 
and thereby regulates cell metabolism [3,4,6,7]. Wnt receptors 
have established a role in the different pathways of cell 
signaling leading to the multiple pharmacological actions, 
including the release of the intracellular calcium stores as a 
result of activation non-canonical Wnt/calcium pathway [8]. 
Activation of the Wnt/β-catenin signaling pathway improves the 
insulin sensitivity and glucose homeostasis in peripheral tissues 
particularly the skeletal muscles as it up-regulates the glucose 
transporters, reduced hepatic glucose production, and promotes 
hepatic insulin sensitivity [9]. Pharmacological inhibition of the 
LRP6 / Wnt-binding domains leads to the suppression of the 
Wnt pathway and its downstream gene regulatory mechanisms 
and inducing hyperglycemia [10,11]. Therefore, any defect in 
the LRP6 has been associated with increased risk of 
dyslipidemia, atherosclerosis and diabetes [12-17]. 
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Malfunction of LRP6 caused impairment of the internalization 
of low- density lipoprotein cholesterol and thereby impaired its 
clearance, which may lead to atherosclerosis [18,19]. Moreover, 
mutation of the LRP6 induced combined hyperlipidemia in term 
of elevated low-density lipoprotein and triglyceride as a result 
of activation of different hepatic pathways, including 
lipogenesis, cholesterol biosynthesis and secretion of 
apolipoprotein B-100 [20]. It is reported that a mutation of the 
LRP6 was found in families with coronary artery disease and 
normal lipid profile, which led to the dysfunction of the 
vascular Wnt signaling and thereby endothelial dysfunction 
[21]. Early-onset of coronary artery disease as a result of 
atherosclerosis is observed in individuals with low plasma 
levels of LRP-6 antagonists without explanation, the 
mechanism of atherosclerosis [22]. Recently, the co-receptors 
LRP-5/6 has been found to play an important role in the 
progression rather than induction of atherosclerosis [23]. There 
is evidence that impairment of the Wnt signaling pathway may 
contribute to inflammation, foam cell formation, endothelial 
dysfunction, pathological angiogenesis and arterial 
calcification, which are an important process in the formation 
and stability of the plaque [24]. In experimental animal models 
of surgical myocardial infarction, it has been found that deletion 
of the LRP5/6 enhances the myocardial ischemic injury [25]. 
Most studies demonstrate a link between coronary artery 
disease and the LRP6 were experimental or genetic.  
      The importance of this study is to use the serum level of 
LRP6 as a discriminator of the severity of coronary artery 
disease. The rationale of this study that patients with myocardial 
ischemia with a positive coronary angiography have progressive 
coronary atherosclerosis and the possibility of altered signaling 
Wtn signaling will arise.  
     Therefore, this study aimed to determine the serum levels of 
the LRP6 as co-receptor of Wnt signaling in patients referred to 
the coronary angiogram taking into considerations the findings 
of coronary angiography, evidence of dyslipidemia, obesity and 
co-existed diabetes mellitus. 
 
Methods 
Study design and the Sampling technique 
Ninety-six consecutive patients undergoing coronary 
angiography for evaluation of coronary artery disease were 
included in this cross-sectional study. The study was conducted 
from September 2016-to January 2017 at the Baquba Teaching 
Hospital, Diyala, Iraq.   
 
Inclusion and exclusion criteria 
The criteria of inclusion are known patients with ischemic heart 
disease, and they treated with a variety of medications that 
included anti-ischemic, antiplatelet, lipid-lowering agents and 
antihypertensive medicines. Patients with cardio-metabolic risk 
factors, including obesity, type2 diabetes, were also included. 
Patients with renal failure, chronic liver disease, terminal 
illness, pregnancy and lactated mothers were excluded.  
 
Clinical and anthropometric measures 
Consultant cardiologists examined each patient prior to the 
coronary angiogram, and the following information and 
measurements were collected; the characteristics data;  
anthropometric measurements; blood pressure levels, glycated 
haemoglobin, fasting serum glucose and lipid profile. Then, the 
patients referred to non-invasive cardiac investigations, 
including electrocardiography and echocardiography. Coronary 
angiogram (using Siemens Artis zeego  03792228, USA) was 
performed, through femoral artery access, under local 
anaesthesia using 1% lidocaine, and heparin is recommended in 
certain situations such as patients with bypass grafting or 
stenotic valve disease. Angiographic coronary artery disease 
was defined as >50% of diameter stenosis in any of the major 
epicardial coronary arteries, while non-obstructed diffuse 
coronary artery disease was defined as involvement of >20 mm 
segment in a particular epicardial vessel. 
 
Biochemical analysis 
At the time of catheterization of the femoral artery, samples of 
the blood drew, and the sera were separated by centrifugation 
for determination of LRP6 levels by using the technique of 
Enzyme-Linked ImmunoSorbent Assay (ELISA). With respect 
to the findings of the coronary angiogram, the patients were 
grouped into Group I (normal coronary angiogram); Group II 
(A: non-obstructed atherosclerotic lesion and B: obstructed 
coronary artery). 
 
Statistical analysis 
The results were expressed as a number, percentage and 
whenever possible as mean ± SD. The serum level of LRP6 as a 
discriminating and depended variable was statistically assessed 
using receiving operating characteristics for measuring the area 
under the curve and 95% confidence interval, and multivariable 
linear regression with ANOVA test for assessing the 
independent variables as predictors. An independent two 
samples t-test for continuous data and Chi-square test for 
categorical data were used to compare the data of two groups. 
For all tests, a two-tailed p ≤ 0.05 was considered statistically 
significant. All calculations and diagrams were made using 
SPSS version 20 programs for Windows.  
 
Results  
Characteristics of the patients 
Ninety-six patients (71 men and 25 women) included in this 
study. There is no significant difference in the mean age 
between study groups (Table 1). At the time of the entry into 
the study, 31.3% of patients had high blood pressure despite 
using antihypertensive agents, and 38.5% were diabetic (Table 
1). Past medical history revealed that 30 out of 96 (31.3%) of 
patients had a previous history of percutaneous cardiac 
catheterization intervention. All the patients were on the 
treatment with statins (of different generations) and antiplatelets 
in term of acetylsalicylic acid and clopidogrel.  
 
Cardiometabolic risk factors 
There are significant high serum levels of cholesterol and low 
serum levels of high-density lipoprotein-cholesterol in Group II 
(A) compared with Group I (Table 2). Group II (B) patients had 
a significant low diastolic blood pressure compared with Group 
I, and they had significantly higher values of fasting 
triglyceride, blood sugar and glycated haemoglobin, and low 
systolic blood pressure compared with Group II A (Table 2). 
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A non-significant higher serum level of LRP6 observed in 
patients with positive angiogram compared with the negative 
angiogram. The mean ± SD of serum LRP6 was 0.160 ± 0.019 
ng/ml in Group I compared with 0.175 ± 0.074 ng/ml in Group  
II A and 0.166 ± 0.063 ng/ml in Group IIB (Figure 1). Further 
statistical analysis using the receiving operating characteristics 
revealed that the area under the curve of patients having two 
and three-vessel lesions were below the reference line of 0.5 
(Table 3 and Figure 2). 
 
Multilinear regression test of cardiometabolic risk factors 
Multilinear regression test of cardiometabolic risk factors (as 
independent factors) and LRP6 (as dependent factor) revealed a 
non-significant correlation (R=0.246, R2=0.061 F=0.86, 
p=0.523) (Figure 3). The standardized coefficients (β) are -
0.137 for body mass index; +0.157 for mean arterial blood 
pressure; 0.094 for blood glucose; +0.146 for triglyceride; 0.029 
for high density lipoprotein-cholesterol; -0.076 for non-high-
density lipoprotein -cholesterol.   
Table 1: Characteristics of the patients 
Characteristics Group I 
(n=6) 
Group II Positive angiogram Probability 
Group II (A) 
 (n=12) 
Group II (B) 
(n-78) 
 
Gender (M: F) 
Age (year) 
Smoking 
Current 
Ex-smoke 
Family history of CAD 
1:5 
58.5±6.5 
 
2 
0 
0 
11:1 
58.9±9.5 
 
3 
2 
0 
59:19 
54.0±7.5 
 
18 
8 
1 
*p=0.001, †p=0.002, ‡0.214 
*p=0.914, †p=0.152, ‡p=0.107 
 
*p=0.710, †p=0.570, ‡p=0.833 
*p=0.289, †p=0.410, ‡p=0.511 
NC 
Concomitant illnesses 
Hypertension 
Diabetes mellitus 
 
1 
2 
 
2 
2 
 
27 
33 
 
*p=1.0, †p=0.369, ‡p=0.215 
*p=423, †p=0.667, ‡p=0.090 
The results expressed as number and mean ± SD.  Group I: normal angiogram, Group II (A): non-obstructed lesion angiogram and Group II (B): obstructed lesion angiogram.  P value was calculated 
by independent two samples t-test for continuous data and by Chi-square test for categorized data. * denotes comparison between Group I and Group II (A); † denotes comparison between Group I and 
Group II (B); ‡ denotes comparison between Group II(A) and Group II (B). M: male, F: female, CAD: coronary artery disease. NC: not calculated because of the zero number. 
 
 
Table 2: Cardiometabolic risk factors 
Risk factor Normal angiogram Positive angiogram Probability 
Group I 
(n=6) 
Group II (A) 
(n=12) 
Group II (B) 
(n=78) 
Body mass index (kg/m2) 32.5±5.5 28.2±3.5 29.5±4.1 *p=0.126, †p=0.241, ‡p=0.284 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Mean arterial blood pressure (mmHg) 
151.7±26.4 
91.7±4.1 
111.6±10.9 
150.5±25.9 
85.3±9.2 
107.0±12.3 
139.1±19.5 
85.4±9.1 
103.3±10.4 
*p=0.930, †p=0.302, ‡p=0.014 
*p=0.058, †p=0.010, ‡p=0.956 
*p=0.429, †p=0.122, ‡p=0.342 
Fasting serum lipid profile (mmol) 
  Total cholesterol 
  Triglyceride 
  High density lipoprotein-cholesterol 
  Low density lipoprotein-cholesterol 
  Non-high density lipoprotein-cholesterol 
 
4.01±1.39 
1.65±1.56 
1.04±0.12 
2.22±0.98 
2.97±1.34 
 
2.93±0.85 
1.45±1.56 
0.81±0.27 
1.46±0.98 
2.12±0.65) 
 
3.49±1.02 
1.77±0.94 
0.97±0.29 
1.72±0.80 
2.52±0.9 
 
*p=0.021, †p=0.510, ‡p=0.065 
*p=0.814, †p=0.889, ‡p=0.039 
*p=0.041, †p=0.346, ‡p=0.089 
*p=0.225, †p=0.389, ‡p=0.252 
*p=0.298, †p=0.551, ‡p=0.094 
Fasting serum glucose (mmol) 
Glycated hemoglobin (mmol) 
6.11±2.44 
36.1±16.8 
5.43±1.24 
31.4±8.6 
6.57±3.21 
39.5±22.3 
*p=0.542, †p=0.067, ‡p=0.031 
*p=0.543, †p=0.656, ‡p=0.027 
The results expressed as mean ± SD. P value was calculated by independent two samples t-test for continuous data. Group I: normal angiogram, Group II (A): non-obstructed lesion angiogram and 
Group II (B): obstructed lesion angiogram. * denotes comparison between Group I and Group II (A); † denotes comparison between Group I and Group II (B); ‡ denotes comparison between Group 
II(A) and Group II (B).  
Table 3: Serum level of low density lipoprotein receptor related protein-6 as a discriminating variable positive angiogram including 
Group IIA (non-obstructed coronary lesion) and IIB (obstructed coronary lesion).  
Coronary blood vessel Area under the curve 95% confidence interval  
Non-obstructed 0.507 0.324-0.690 
One vessel obstruction 0.542 0.408-0.676 
Two vessels  obstruction 0.492 0.354-0.630 
Three vessels  obstruction 0.462 0.325-0.599 
Null hypothesis: true are=0.5. Any value below 0.5 indicates a significant low levels of Serum level of low density lipoprotein receptor related protein-6    
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Figure 1 Serum levels of low density lipoprotein receptor related protein-6 (LRP6) according to the result of the coronary artery angiography. Group I: normal angiogram, 
Group IIA: non-obstructed lesion angiogram and Group IIB: obstructed lesion angiogram. The probability of statistical difference between groups is > 0.5 
 
Multilinear regression test of cardiometabolic risk factors 
Multilinear regression test of cardiometabolic risk factors (as 
independent factors) and LRP6 (as dependent factor) revealed a 
non-significant correlation (R=0.246, R2=0.061 F=0.86, 
p=0.523) (Figure 3). The standardized coefficients (β) are -
0.137 for body mass index; +0.157 for mean arterial blood 
pressure; 0.094 for blood glucose; +0.146 for triglyceride; 0.029 
for high density lipoprotein-cholesterol; -0.076 for non-high-
density lipoprotein -cholesterol.   
  
Discussion 
The results of this study show that serum level of LRP6 is a 
useful predictor of the severity of coronary artery disease that 
assessed by a coronary angiogram and this prediction does not 
relate to the modifiable cardiometabolic risk factors. The 
changes in the serum LPR6 don't relate to the age factor, as 
there are no significant differences in the age between the 
studied groups [26]. The discrepancy in the results of the 
modifiable risk factors, including the blood pressure, fasting 
serum lipid profile and glucose due to the medications used by 
the patients. However, alteration in the LRP6 levels can occur 
in familial coronary artery disease with normal lipid profile 
levels and may be due to gene mutation of Wnt signaling 
pathway [17]. There is no doubt that the serum LRP6 is a 
predictor of diabetes mellitus, but its level in diabetic patients 
did not differ from control subjects [16,27]. Therefore, our 
results that showed the serum level of LRP6 is not correlated 
and predicted the non-modifiable factors (Figure 3) are in 
agreement with others as our patients have abnormal values of 
modifiable factors and they were on the treatment. It is 
important to emphasize here that identification of the mutation 
of the LRP6 is not carried on in this study, and it is possible that 
there is a mutation of LRP6 among the participants, and this 
speculation reflected on the non-significant correlations that  
 
illustrated in figure 3. Moreover, malfunction of LRP6 did not 
produce specific abnormalities in the lipid profile, and as 
mentioned before, it induced combined hyperlipidemia [20]. 
The interesting finding in this study is the association between 
the serum levels of LRP6 and the number of obstructed 
coronary vessels (Table 3 and Figure 2). The area under the 
curve of LRP6 tended to be less than 0.5, which indicated that 
patients with two-three coronary artery obstruction have low 
serum levels. Cheng et al. found that LRP6 promotes the 
osteochondrogenic cell differentiation and it limits the 
arteriosclerosis calcification in an experimental animal model, 
that is, a decrease in the LRP6 levels plays a role in the 
reducing the vascular smooth muscle lineage [28]. Another 
experimental study showed that when the activity of LRP6 is 
reduced, the medial hyperplasia of the artery occurs due to the 
loss of vascular muscle differentiation [29]. The possible 
explanation of the loss of the LRP6 activity and the coronary 
artery disease in human is due to the mutation of the LRP6 gene 
[30,31]. Polymorphism of the LRP6 gene was also associated 
with a sporadic coronary artery disease [32]. One of the 
limitations of the study is the small sample size of Group I and 
Group II A because the design of this study was depended on 
the findings of a coronary angiogram. The other limitation of 
the study is the existence of cardio-metabolic risk factors which 
cannot be avoided because it is hard to recruit ischemic heart 
disease patients without risk factors and it is unethical to do a 
coronary angiogram to healthy subjects. 
 
Conclusion 
We conclude that serum levels of LRP6 are a good 
discriminator of patients with coronary artery disease as the 
area under the curve of the serum levels of LRP6 is 
significantly decreased as the number of occluded coronary 
vessels increased. 
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Figure 2 Area of the under the curve of the serum levels of low density lipoprotein receptor related protein-6 (LRP6) according to the angiograph findings characterized by 
the number of the obstructed coronary artery. 
 
 
Figure 3 Multivariable liner regression plot taking the serum level of LRP6 as dependent factor and the cardiometabolic risk factors; body mass index, mean arterial blood 
pressure, blood glucose, triglyceride, high density and non-high density lipoproteins as independent factors. The serum cholesterol variable is excluded by the test because 
of non-linearity. 
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